skip to main |
skip to sidebar
Researchers at Johns Hopkins found that a safe and inexpensive antibiotics commonly used to treat acne since the 1970s can make HIV or the virus that causes AIDS was asleep and prevents the virus active again and multiply.
Antibiotic called minocycline may improve current treatment regimens for HIV-infected patients when used in combination drug standards based HAART (Highly Active Antiretroviral Therapy). New research published online this will be printed in the Journal of Infectious Diseases 15 th edition of April.
"Strong gains using minocycline is that the virus appears less so that they can develop drug resistance because minocycline is in the path of the target cells rather than viral proteins," says Janice Clements, Ph.D., vice dean of faculty and professor of molecular and comparative Pathobiology at the Johns Hopkins University School of Medicine, as reported from MedicalNewsToday, Tuesday (23/3/2010).
According to Clements, a major challenge when treating patients with HIV is a virus that remains locked in a state of inactivity. ART (Antiretroviral Therapy) really effective to reduce replication (duplicate) an active, minocycline is another way of defense against viruses.
Unlike drugs used in antiretroviral therapy that targets the virus, the target of minocycline is immune cells known as T cells According to Clements, minocycline reduces the ability of T cells to the active and multiply, two important steps in the production and progression of HIV to AIDS.
HAART HIV are usually able to protect people from illness, but it's not a cure. HIV virus is maintained at a low level but never fully cleaned. The virus remains in hiding secretly in the immune cells. If a person stops taking HAART or missed dose, the virus can become active again, out of immune cells and start to spread.
The idea to use in addition to HAART minocycline appears when the Hopkins research team conducted a study on arthritis patients who show anti-inflammatory effects of minocycline on T cells
Tim Hopkins connects with previous studies, which showed that treatment with minocycline has many beneficial effects on monkeys infected with SIV, the primate version of HIV. Minocycline-treated monkeys, the virus load in cerebrospinal fluid and viral RNA in the brain significantly decreased. It also shows the influence of T cell activation and proliferation
"Because minocycline can reduce T cell activation, you may think it will harm the immune system in monkeys, which is very similar to humans, but we did not see adverse effects," said Gregory Szeto, a graduate student in the Department of Cellular and Molecular Medicine who worked on Retrovirus Laboratory in Hopkins.
According to him, this drug in a good balance, and ideally for HIV because of their target very specific aspects of immune system activation.
Success in monkey studies that encourage the team to study whether minocycline treatment effect on latency in human T cells infected by HIV. The team uses human cells infected with HIV on HAART, to isolate the immune cells are "resting" and treated with minocycline half.
"Minocycline reduces the ability of the virus to exit infected resting T cells," Szeto. This prevents the virus to escape on a person who used HAART, and therefore can prevent the activation of the virus, maintain the level of viral latency or even lowered.
Researchers at Johns Hopkins found that a safe and inexpensive antibiotics commonly used to treat acne since the 1970s can make HIV or the virus that causes AIDS was asleep and prevents the virus active again and multiply.
Antibiotic called minocycline may improve current treatment regimens for HIV-infected patients when used in combination drug standards based HAART (Highly Active Antiretroviral Therapy). New research published online this will be printed in the Journal of Infectious Diseases 15 th edition of April.
"Strong gains using minocycline is that the virus appears less so that they can develop drug resistance because minocycline is in the path of the target cells rather than viral proteins," says Janice Clements, Ph.D., vice dean of faculty and professor of molecular and comparative Pathobiology at the Johns Hopkins University School of Medicine, as reported from MedicalNewsToday, Tuesday (23/3/2010).
According to Clements, a major challenge when treating patients with HIV is a virus that remains locked in a state of inactivity. ART (Antiretroviral Therapy) really effective to reduce replication (duplicate) an active, minocycline is another way of defense against viruses.
Unlike drugs used in antiretroviral therapy that targets the virus, the target of minocycline is immune cells known as T cells According to Clements, minocycline reduces the ability of T cells to the active and multiply, two important steps in the production and progression of HIV to AIDS.
HAART HIV are usually able to protect people from illness, but it's not a cure. HIV virus is maintained at a low level but never fully cleaned. The virus remains in hiding secretly in the immune cells. If a person stops taking HAART or missed dose, the virus can become active again, out of immune cells and start to spread.
The idea to use in addition to HAART minocycline appears when the Hopkins research team conducted a study on arthritis patients who show anti-inflammatory effects of minocycline on T cells
Tim Hopkins connects with previous studies, which showed that treatment with minocycline has many beneficial effects on monkeys infected with SIV, the primate version of HIV. Minocycline-treated monkeys, the virus load in cerebrospinal fluid and viral RNA in the brain significantly decreased. It also shows the influence of T cell activation and proliferation
"Because minocycline can reduce T cell activation, you may think it will harm the immune system in monkeys, which is very similar to humans, but we did not see adverse effects," said Gregory Szeto, a graduate student in the Department of Cellular and Molecular Medicine who worked on Retrovirus Laboratory in Hopkins.
According to him, this drug in a good balance, and ideally for HIV because of their target very specific aspects of immune system activation.
Success in monkey studies that encourage the team to study whether minocycline treatment effect on latency in human T cells infected by HIV. The team uses human cells infected with HIV on HAART, to isolate the immune cells are "resting" and treated with minocycline half.
"Minocycline reduces the ability of the virus to exit infected resting T cells," Szeto. This prevents the virus to escape on a person who used HAART, and therefore can prevent the activation of the virus, maintain the level of viral latency or even lowered.
0 komentar:
Posting Komentar